Concomitant Actionable Mutations and Overall Survival (OS) in Egfr-Mutant Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Included in The Eurtac Trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3)
Year: 2012
Type: article
Source: Annals of Oncology
Institutions: Institut Català d'Oncologia, Hospital General Universitario de Alicante Doctor Balmis, USP Institut Universitari Dexeus, Instituto Oncológico Dr. Rosell, Nanjing Drum Tower Hospital, Centre Hospitalier Universitaire de Limoges, Hôpital Universitaire Dupuytren, Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Azienda Ospedaliera San Camillo-Forlanini, Vall d'Hebron Hospital Universitari, Centre François Baclesse, University of Messina, Hospital de Sant Pau, Complexo Hospitalario Universitario A Coruña, Hospital Universitario Virgen del Rocío
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3000607645